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Background: The Living with Pulmonary Hypertension questionnaire (LPH) was adapted from the Minnesota Living
with Heart Failure Questionnaire for use in patients with pulmonary arterial hypertension (PAH). Study objectives
were to confirm the face and content validity, to assess the structure and psychometric properties, and provide
guidance for the interpretation of the LPH.
Methods: A qualitative interview study was conducted with PAH patients in the US (n=12), Germany (n=14) and
France (n=12) to evaluate the face and content validity of the LPH. Psychometric validation was performed using
blinded data from a double blind, Phase III, clinical trial (n=196). Validation analyses were performed on baseline
and week 12 (visit 6/last visit) data and included evaluation of: item response distributions, quality of completion,
construct validity, reliability, clinical validity and responsiveness. Analyses to provide an estimation of the Minimal
Important Difference (MID) for the LPH scores were performed.
Results: Cognitive debriefing interviews with 38 PAH patients indicated that the most commonly reported PAH
symptoms and impacts are covered by LPH items. Patients found the LPH questionnaire relevant and comprehensive
to their experience. Some suggestions were made to enhance the face validity of the LPH. The content validity of the
questionnaire was supported. Results of the psychometric validation analyses (n=190) indicated that the LPH Emotional
and Physical scores met the criteria for convergent and discriminant validity; for the total score all but two items met
the test for item convergent validity. Internal consistency reliability was demonstrated by Cronbach’s alpha values
of >0.70 for all LPH scores. The LPH Physical and Total scores discriminated between World Health Organisation (WHO)
Functional classes and 6 Minute walk test distances, indicating clinical validity and were also responsive to change in
clinical severity, as measured by change in WHO functional class and Borg CR 10 Scale. Further investigation is required
to confirm the responsiveness of the Emotional score. Estimation of MID using distribution-based methods indicated a
change of 3 points for the sub-scales and 7 for the total score to be clinically meaningful.
Conclusion: The LPH is a valid and reliable instrument that meets FDA criteria.
Keywords: Pulmonary arterial hypertension, Face and content validation, Psychometric validation, Living with
pulmonary hypertension questionnaireBackground
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare lung
disorder with current estimates suggesting the preva-
lence of PAH in the US is 109 per million individuals
[1]. In PAH, pulmonary vascular injury leads to vessel* Correspondence: nicola.bonner@adelphivalues.com
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reproduction in any medium, provided the orremodeling and subsequent narrowing of the pulmonary
arterioles that in turn, increases afterload on the right
ventricle. As this disease progresses and afterload in-
creases, right ventricular failure ensues that ultimately
leads to death [2]. While the initial symptoms of PAH
are non-specific, including shortness of breath (dyspnea)
[3] and fatigue following physical exertion, these often
progress to occur with minimal exertion or, in extreme
cases, at rest [4]. Additionally, patients often experienceLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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skin (cyanosis); chest pain; and palpitations [5].
Such debilitating symptoms result in substantial impair-
ments in patients’ Health-Related Quality of Life (HRQoL)
[6]. In particular, PAH results in significant impairment in
physical functioning, ability to perform activities of daily
living and social functioning, and many patients experi-
ence feelings of depression and anxiety and difficulties
sleeping [7-9]. To evaluate treatment benefit, primary and
key secondary endpoints in PAH clinical trials are typic-
ally clinical measures focused on sub-maximal exercise
capacity (e.g. the six minute walked distance [6MWD]).
However, to complement such trial endpoints, rigorous
measurement of HRQoL related to PAH is also recom-
mended to ensure treatments and interventions improve
not just objective functional capacity, but also the day-
to-day well-being of patients. To date, HRQoL measure-
ment in trials has typically relied on generic measures
which may not fully evaluate the specific impacts experi-
enced by PAH patients [10,11]. Few disease-specific mea-
sures of quality of life (QoL) in PAH exist and are limited
by the lack of explicitly defined responsiveness and clinical
utility [12]. Thus, we sought to develop and assess a PAH-
specific tool to measure HRQoL in this patient population
by modifying an existing disease-specific metric of QoL in
left heart failure, the Minnesota Living with Heart Failure
questionnaire (MLHF). Further, we sought to define a min-
imal important difference for this new tool, the Living with
Pulmonary Hypertension Questionnaire (LPH).
Methods
Objectives
The objectives of this work were to select and adapt an
existing disease- specific measure of HRQoL for use in
PAH populations and then to confirm the face and con-
tent validity and scoring and psychometric properties of
the selected instrument. Specific objectives of the face
and content validity testing of the LPH questionnaire were:
to explore the item coverage of key symptoms and impacts
of PAH; to explore whether the items, instructions, recall
period and response options are relevant, well-understood
and interpreted in a consistent manner by patients with
PAH; and to identify any changes to the wording of the
LPH that are recommended as a result. Specific objectives
of the assessment of the psychometric properties of the
LPH were: to confirm the item-scale structure of the LPH;
to assess the reliability, validity and responsiveness of the
LPH; and to provide guidance on the interpretation of
LPH scores and changes in scores.
Development of a conceptual model
Qualitative and quantitative PAH literature was reviewed
to support the development of a conceptual model of
PAH (Figure 1). The model includes a summary of clinicalcharacteristics of PAH; symptoms experienced by patients
and the resulting functional impairments, and available
treatment options. The conceptual model was used as basis
for a review of existing HRQoL instruments and to explore
appropriate outcome measures to assess PAH. The instru-
ment review identified only one PAH-specific instrument
the Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR) [12]. Although the CAMPHOR had been
developed for specific use in PAH and there was evidence
of the reliability and validity of the instrument [12] there
were concerns about the concept coverage; there is no
evidence that saturation analysis was conducted to con-
firm that all concepts important to patients were cap-
tured, mapping of the CAMPHOR concepts to the PAH
conceptual model identified key concepts such as dizzi-
ness, chest pain and palpitations were missing from the
CAMPHOR. There were also concerns about the length
of the instrument (65 items) and the dichotomous format
of some of the response options. Such factors would be a
concern for regulatory agencies such as the FDA and may
impact on the content validity and responsiveness of the
instrument [13].
Given the concerns about the CAMPHOR, the MLHFQ
[27] was identified as a stronger instrument, that provided
better measurement and more comprehensive coverage
of PAH symptoms and impacts. Moreover, there is evi-
dence of previous use in PAH clinical trials [14,15,28,29],
and that it is responsive to changes following treatment
in PAH [15,29-31]. The MLHFQ however, is specific to
heart failure. In order to make the instrument appro-
priate for use in patients with PAH, minor modifica-
tions were made to the MLHFQ. Modifications included:
changes to the wording of some of the questions and in-
structions to be specific to PAH rather than heart failure,
and a revision to the recall period from four weeks to
one week. The reduction in the recall period to one week
was considered an important modification in order to en-
sure the instrument met the FDA preference for “short
recall periods” [13]. This work was conducted in order
to provide a suitable instrument for the assessment of
PAH symptoms in a clinical trial to benefit PAH pa-
tients across the globe.
Qualitative patient interviews
After obtaining the relevant institutional review board
approval (approval codes: 2009-P-001852/2, MAPI-10-242,
B-F-2010-033, 09/2295), qualitative patient interviews were
conducted to evaluate the content validity of the LPH. The
qualitative interviews were conducted in the US, France
and Germany and included patients with PAH as defined
by current consensus guidelines [32] who were at least 18
years of age and had provided written informed consent.
The MLHFQ had previously been translated and linguistic-
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Endothelin receptor antagonists [15,16,21,25]
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Pulmonary Arterial Hypertension
Figure 1 PAH Conceptual Model [6-9,12,14-26].
Bonner et al. Health and Quality of Life Outcomes 2013, 11:161 Page 3 of 16
http://www.hqlo.com/content/11/1/161either treatment naïve or had previously received treatment
with an endothelin receptor antagonist (ERA), a phos-
phodiesterase type 5 inhibitor (PDE5I), or a prostacyclin
analogue. Patients were required to have cognitive and lin-
guistic capacities sufficient to allow them to actively par-
ticipate in an interview, as determined by the recruiting
physician. Patients with significant psychiatric disease were
excluded from the study. Patients with a diagnosis of other
relevant pulmonary diseases including pulmonary hyper-
tension other than PAH, moderate to severe obstructive
lung disease, or severe restrictive lung disease were ex-
cluded from the study [32].
Interviewers trained in qualitative research, native to
each country, followed a semi-structured interview guide.
The guide included both open-ended questions about
patient experiences of PAH and a cognitive debriefing exer-
cise to assess the patient’s understanding of the instruc-
tions, items, response options and recall period of the
LPH. Examples of open-ended questions exploring the pa-
tient experience of PAH included:
“What is it like to have PAH?”
“Please tell me about any symptoms or problems that
you experience, if any? When do you usually
experience these symptoms? How long do thesesymptoms normally last for? In what ways do these
symptoms affect you, if at all?”
“Does your PAH ever stop you from doing things? (e.g.
housework, going out, hobbies) If yes please explain”
The cognitive debriefing part of the interview asked
the patients general questions about the LPH question-
naire such as:
“What is your overall opinion of this questionnaire?
Where there any questions that were unclear or
difficult to answer? If yes, which? What made this/
these questions difficult to answer?”
“What did you think about having to think about your
symptoms over the past week?”
“Do you think it was relevant to think about your
symptoms over the past week?”
Patients were also asked specific questions about each
item or instruction, for example:
“What did you think of this question? What did this
question mean to you, in your own words?”
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understand in this question? How would you reword it
to make it clearer”
“How far back were you thinking when you answered
this question? How long do you thinking this question
was asking you to think back over?”
“Do you think the response options for this question
are appropriate? Would you change them in any
way?”
Procedures were implemented to capture any ad-
verse events reported during the interviews; no adverse
events were reported. Qualitative analysis of verbatim
transcripts was performed using Atlas Ti software andTable 1 LPH Validation analyses
Analysis performed Description
Quality of completion of the LPH A description of the level
during the study.
Description of the items of the LPH The frequency and perce
described for each of the
Description of the baseline LPH population Patient parameters includ
class, 6MWD and Borg CR
Confirmation of the structure of the LPH Multitrait analysis was use
dimensions. This analysis a
Correlation coefficients be
also calculated. Confirmato
Description of the LPH Scores The distribution of the LP
described. The frequency
score was described.
Internal consistency reliability Internal consistency refer
and reflect a single unde
internal consistency reliab
criterion for acceptable in
baseline (V0) on the base
score and for the Physica
Clinical Validity Clinical validity evaluates
patients with different cli
scores were described ac
Responsiveness Responsiveness refers to
responsiveness of the LPH
after 12 weeks. Change in
functional class (improved
functional class; worsened
in 6MWD > 50; stable: -50
CR10 Scale (improved: cha
worsened: change in Borg
Minimal Important Difference (MID) Analyses to provide an es
methods exist to estimat
distribution-based meth
0.2 × STDBL [46] and as 0.
was also used as a distrib
deviation at V0 and r the
between V0 and V6 on th
of they changed to a lowe
if the 6MWD increased by
as ‘minimally improved’ ifMicrosoft Excel and methods derived from Grounded
Theory [33]. French and German transcripts were trans-
lated into English prior to analysis. To determine whether
all of the symptoms and impacts of importance to pa-
tients with PAH had been elicited during the inter-
views, the patient interview sampling strategy and
analysis followed the principle of ‘saturation’. Satur-
ation is defined as the point where no ‘new’ informa-
tion on a particular item or topic is mentioned by
patients [34]. Interviews were analyzed in a stepwise
manner to determine the point at which saturation was
reached.
Psychometric validation study
Psychometric validation of the LPH was performed
using blinded data from a double blind, Phase III clinicalof completion of the LPH was performed on all questionnaires received
ntage of responses for each response choice, including missing data was
LPH items.
ing age, gender, height and weight, blood pressure level, WHO functional
10 scale score were described at baseline.
d to confirm the item groupings in the Physical and Emotional LPH
lso served to test the item convergent validity criterion of the Total score.
tween the Total score and Physical and Emotional dimension scores were
ry Factor Analysis (CFA) was used to confirm the structure of the LPH.
H scores and changes in scores between baseline and week 12 was
and percentage of patients scoring at floor and ceiling for each LPH
s to the extent to which individual items are consistent with each other
rlying construct. Cronbach’s alpha statistic is commonly used to assess
ility. A Cronbach’s alpha coefficient of >0.70 is typically used as the
ternal consistency reliability [41,42]. Cronbach’s alpha was calculated at
line LPH population and at V6 on the V6 LPH population for the total
l and Emotional dimension scores of the LPH.
the extent to which the questionnaire is able to detect variability among
nical severity levels. The LPH Total and Physical and Emotional dimension
cording to WHO functional class, 6MWD and Borg CR 10 Scale.
the ability of a measure to detect clinically important changes [43]. The
Total score and Physical and Emotional dimension scores was assessed
scores from baseline was assessed according to change in WHO
: change to a lower WHO functional class; stable: no change in WHO
: change to a higher WHO functional class), 6MWD (improved: change
≤ change in 6MWD ≤ 50; worsened: change in 6MWD <−50) and Borg
nge in Borg CR 10 Scale < 1; stable: -1 ≤ change in Borg CR 10 Scale ≤ 1;
CR 10 Scale > 1) [44].
timation of MID for the LPH scores were performed [45]. Two types of
e the MID: distribution-based and anchor-based methods. The main
od was based on Cohen’s effect-size; the MID was calculated as
5 × STDBL, with STDBL the standard deviation of the score at V0. The SEM
utional estimate of MID; it was calculated as, where STDBL is the standard
reliability coefficient. Within the anchor-based methods change in scores
e WHO functional class (patients were considered ‘minimally improved’
r functional class), 6MWD (patients were considered ‘minimally improved’
50m between V0 and V6) and Borg CR10 scale (patients were considered
their scale decreased by 1 between V0 and V6) were used as anchors [44].
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Visit 1 (V1), and were then followed for 12 weeks. The
LPH was self-administered at V0 (baseline) and V6 (12
weeks or last visit), the V6 time point was used for
cross-sectional analyses. Patients with PAH, defined as
per consensus guidelines, aged between 18 and 75 years
of age, whose six-minute walk distance (6MWD) was be-
tween 150 and 450m were enrolled [32]. Patients were
either treatment naïve or had previously received treat-
ment with an ERA or a prostacyclin analogue. Patients
were excluded from the trial if they were unable to per-
form the six-minute walk test (6MWT), had taken intra-
venous (IV) prostacyclin analogues, or PDE5I within the
90 days prior to visit 1.Table 2 Key demographic and clinical characteristics of the q










Highest education level n (%)
Primary school 0
Before high school 0
Some high school 0
High school diploma or GED 4 (33
Some years of college 1 (8.3
Certificate program 0
College or university degree (2 or 4 year) 5 (41




Time since patient first diagnosed with PAH? (years)
Mean 2.2
Median 1.5
Min, max 0, 6
Duration of current PAH treatment? (months)
Mean 15.8
Median 12
Min, max 1, 48
Missing data 1
*Education level reflects patient response that they received ‘no education’.Measures
LPH Questionnaire
The LPH derived from the MLHF questionnaire com-
prises 21 items, responded to on a 6-point Likert scale
ranging from 0 ‘No’ to 5 ’Very much’. A total score ran-
ging from 0 to 105 is calculated by summing the re-
sponses to all 21 questions. A physical dimension score
(range 0–40, 8 items) and an emotional dimension score
(range 0–25, 5 items) can also be calculated. For all LPH
scores, a higher score indicates that patients are more af-
fected by their medical condition. The MLHFQ from
which the LPH was derived has shown to be highly reli-
able as demonstrated by the correlation between re-
peated baseline assessments (r=0.93) [27]. The MLHFQualitative interview study sample (N=38)
Germany France Total




31, 85 25, 80 25, 85
) 3 (21) 2 (16.7) 8 (21.1)
) 11 (78.6) 10 (83.3) 30 (78.9)
0 3 (25) 3 (7.9)
0 1 (8.3) 1 (2.6)
0 0 (0) 0 (0)
.3) 2 (14.3) 4 (33.3) 10 (26.3)
) 0 1 (8.3) 2 (5.3)
4 (28.6) 0 (0) 4 (10.5)
.6) 0 2 (16.7) 7 (18.4)
.7) 7 (50) 0 (0) 9 (23.7)
0 1 (8.3) 1 (2.6)




0, 8 2, 29 0, 29
37.9 42.3 31.7
23 36 21.5
2, 95 0, 168 0, 168
0 1 2
Table 3 Linking patient descriptions of PAH symptoms to
LPH items
Symptom* LPH item(s) assessing concept
Shortness of breath (n=32)
12. making you short of breath?
Difficulty breathing (n=15)
Tiredness (n=34) 13. making you tired, fatigued or
lacking energy?Fatigue (n=16)
Exhaustion (n=14) 2. making you sit or lie down to
rest during the day?Weak (n=7)
Swelling in the ankles or legs
(edema) (n=31)
1. causing swelling in your ankles,
legs?
Dizziness (n=13)
No item to assess this symptom
Fainting spells (n=7)
Palpitations (n=6) No item to assess this symptom
Headache (n=9) No item to assess this symptom
Problems with limbs (n=7) No item to assess this symptom
* Symptoms reported by 5 or more patients.
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MLHFQ scores according to New York Health Associ-
ation (NYHA) functional class supported the clinical val-
idity of the MLHFQ [27]. It should be noted that these
properties are relevant to patients with heart failure, not
PAH. The MLHFQ has been used previously in PAH
clinical trials. Cenedese et al. used the MLHFQ in a
study of patients with PAH and chronic thromboembolic
pulmonary hypertension (CTEPH). This study supported
the internal consistency and test-retest reliability of the
instrument in PAH and CTEPH patients as well as the
clinical and concurrent validity and responsiveness [30]. In
addition to the study by Cenedese et al [30] the MLHFQ
has previously been used in other PAH clinical trials, where
it has shown evidence of responsiveness to change follow-
ing treatment [15,29,31].
6MWT
The 6MWT was conducted according to American Thor-
acic Society guidelines [35]. Specifically, the test was
performed indoors, along a long, flat, straight, enclosed
corridor of at least 30 meters in length. The 6MWT was
conducted unencouraged by a person not involved in the
titration of the study drug, who was unaware of the imme-
diate reaction of the patient’s blood pressure and heart
rate after dosing.
The Borg CR10 scale
The Borg Category Ratio 10 (CR10) Scale was measured
in conjunction with the 6MWD Test during the clinical
trial. Patients are asked to rank their exertion at the end
of the 6MWD test on a scale with the lowest rating be-
ing ‘0 Nothing at all’ up to the patients being able to rate
their exertion as a ’12 or still higher’ which represents
“Absolute maximum”. The Borg CR 10 Scale has been
shown to be a valid and reliable measure for the estima-
tion of perceived intensity [36,37].
World Health Organisation (WHO) functional class
Patient’s functional class was determined by the study in-
vestigator using WHO classification: [38] Class I: Patients
with PH but without resulting limitation of physical activ-
ity; Class II: Patients with PH resulting in slight limitation
of physical activity; Class III: Patients with PH resulting in
marked limitation in physical activity; Class IV: Patients
with PH with inability to carry out any physical activity.
EuroQol-5D (EQ-5D)
The EQ-5D is a standardized, self-report measure of
health status. Patients describe their health state within
the domains of “Mobility”, “Self-Care”, “Pain/Discomfort”
and “Anxiety/Depression” on a 3 level scales, with 1
reflecting the better health state, and rate their overall
health status on a visual analogue scale (VAS) of 0 ‘Worstimaginable health state’ to 100 ‘Best imaginable health
state’ [39]. The test-retest reliability of the EQ-5D has been
shown to be acceptable (ICC>0.7) across a range of disease
areas [40], the clinical validity of the EQ-5D has been con-
firmed in patients in a variety of disorders.
Analysis
Demographic, clinical, and functional data were summa-
rized using means and standard deviations, medians and
ranges, or proportions where appropriate. Table 1 presents
a summary of the analyses performed as part of the valid-
ation of the LPH. Test-retest reliability could not be
analysed as part of this study given the clinical trial context
and the fact that most patients experienced a change in
their condition due to receiving treatment. Thus there
were limited numbers of stable patient data with which to
perform test-retest reliability analysis. All data processing
and analyses were performed with SAS software for Win-
dows version 9.2 (SAS Institute, Cary, NC, USA).
Results
Qualitative patient interviews
Interviews were conducted with 38 PAH patients (US
n=12, Germany n=14 and France n=12). Demographic
and clinical characteristics were broadly comparable
across country samples, although patients in France had
been diagnosed for longer than patients in the US and
Germany (Table 2). Although, this may mean their symp-
toms were more under control, it provided a greater depth
of symptom experience.
The symptoms and domains of impact reported by pa-
tients during the open-ended part of the interviews were
mapped onto the LPH items to assess content validity of
the LPH. Table 3 presents the symptoms reported by five
Table 4 Linking patient descriptions of the impact of PAH to LPH items
Impact* LPH item(s) assessing concept
Activities of daily living
Jobs around the home (n=36) 4. making it difficult to work around the house or in the garden?




Caring for children (n=6)
Laundry (n=6)
Vacuuming (n=6)
Looking after animals (n=5)
Cognitive impacts





Worry (n=32) 19. making you worry?
Depression (n=28) 21. making you feel depressed?








Climbing stairs (n=37) 2. making you sit or lie down to rest during the day?
Walking (n=36) 3. making it difficult to walk about or climb stairs?
Exercise/sports (n=34) 4. making it difficult to work around the house or in the garden?
Leisure activities (n=33) 5. making it difficult to go anywhere away from home?
Carrying things (n=23) 7. making it difficult to have relationships or do things with your friends
or family?




Control of own life (n=26) 18. making you feel a loss of self-control in your life?
Impact on relationships
Relationships with friends and family (n=29) 7. making it difficult to have relationships or do things with your friends
or family?
Sexual activities (n=26) 10. making your sexual activities difficult?
Doing things with friends and family (n=21) 17. making you feel you are a burden to your family or friends?
Having to rest during the day
Rest during the day (n=35) 2. making you sit or lie down to rest during the day?
Rest during activities (n=20)
Rest after activities (n=10)
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Table 4 Linking patient descriptions of the impact of PAH to LPH items (Continued)
Impact on sleep
Problems with sleep (n=22) 2. making you sit or lie down to rest during the day?
Problems getting to sleep (n=11) 6. making it difficult to sleep well at night?
Quality of sleep (n=9)
Problems staying asleep (n=8)
Position of sleep (n=5)
Social impact
Social isolation (n=11) 7. making it difficult to have relationships or do things with your friends
or family?
Lack of support and recognition of symptoms by friends
and relatives (n=11)
17. making you feel you are a burden to your family or friends?
Socializing (n=7)
General social impact (n=6)
Treatment impact 16. giving you side effects from treatments?
Treatments intrusive and burdensome (n=10) 15. costing you money for medical care?
Work impact (n=28) 8. making it difficult to work to earn a living?
Positive impacts
Support from friends and family (n=14) 7. making it difficult to have relationships or do things with your friends
or family?
Impact on eating/diet (n=31) 11. making you eat less of the things you like?
Impact on going out
Going out of the house (n=25) 5. making it difficult to go anywhere away from home?
Travel (n=18)
Preventing from going out (n=10)
Going on vacation (n=7)
Impact on others
Burden to others (n=20) 7. making it difficult to have relationships or do things with your friends
or family?
Dependence on others (n=10) 17. making you feel you are a burden to your family or friends?
Impact on husband or wife (n=9)
Needing support (n=9)
Impact on family (n=6)
Financial impact 15. costing you money for medical care?
High cost of medication (n=20)
* Impacts reported by 5 or more patients.
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items in the LPH. The results indicate that the key symp-
toms of PAH are captured by the LPH, supporting the face
and content validity of the LPH with respect to the meas-
urement of PAH symptoms. A number of other symptoms
were reported by fewer than five patients each that are not
assessed by the LPH. The majority of these symptoms are
considered ‘signs’ rather than symptoms of PAH and there-
fore would not be appropriate to assess.
Table 4 presents the impacts reported by patients dur-
ing the interviews and links them to items on the LPH.Patient interviews confirmed that the key impacts of PAH
(those reported by five or more patients) are assessed by
the LPH. For most impact concepts, there was sufficient
coverage in the LPH; however, within the cognitive and
emotional impact concepts there were some impacts
reported that are not directly assessed. Within the cogni-
tive concept, memory (n=26), concentration (n=24), focus
(n=6) and motivation (n=5) were reported. Concentration
and memory are assessed by the LPH. Focus is not directly
assessed, although during the interviews patients described
focus to be similar to concentration and therefore thus
Table 5 Description of the baseline LPH population
(N=190)
Variable [a] Baseline LPH population
(N=190)
Age
n (missing) 190 (0)
Mean (SD) 48.1 (16.3)
Median 48.0






Class I 7 (3.7%)
Class II 79 (41.6%)
Class III 101 (53.2%)
Class IV 2 (1.1%)
Missing 1 (0.5%)
6 Minute Walking Test at baseline
n (missing) 188 (2)
Mean (SD) 365.0 (67.7)
Median 380.0
Min - Max 160.0-468.0
Borg Score at baseline
n (missing) 187 (3)
Mean (SD) 3.8 (2.1)
Median 3.0
Min - Max 0.0-10.0
[a] Missing data included in calculation of percentages.
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tivation, which was only reported by five of the 38 patients,
is not assessed. A large number of emotional impacts were
reported, the key impacts of worry (n=32), depression
(n=28) and worry about the future (n=18) are assessed.
Given these findings it can be concluded that the key im-
pacts to patients with PAH are captured by the LPH thus
supporting its content validity.
The second part of the patient interviews involved
cognitive debriefing of the LPH to confirm the level of
understanding and relevance of the questionnaire to
PAH patients. The majority of patients found the ques-
tionnaire resonated with their experience of PAH. In
terms of the response options, the majority of the pa-
tients felt that the range of response options was appro-
priate. Some patients suggested adapting the response
options or making them more specific to certain ques-
tions. While these suggestions could be taken into con-
sideration for future versions of the LPH, the issues
raised did not detract from patients’ ability to actually
complete the questionnaire. Some areas to improve un-
derstanding were raised; these included highlighting the
instructions to the patient to ensure they do not miss
them, adapting the response options to ease completion
and splitting items assessing multiple concepts into sep-
arate items. Not all patients appeared to use the recall
period of one week when completing the items. The
interview setting may have been one cause for this, be-
cause patients did not have a clear timeframe in which
to consider their symptoms. A number of patients spe-
cifically commented that they liked the questionnaire
and thought it captured appropriate symptoms. Sixteen
of the patients specifically reported that they found the
questionnaire ‘easy’ or ‘simple’ to complete.
Psychometric validation study
The total psychometric validation population (patients
who returned an LPH questionnaire at V0 or V6) in-
cluded 196 patients, 190 of whom were included in the
baseline population (patients who completed at least
90% of LPH items at V0), and were included in all ana-
lyses conducted on baseline data. The week 12 popula-
tion (patients who completed at least 90% LPH items
at V6) included 176 patients who were included in all
analyses conducted on week 12 data. The responsiveness
population (patients who completed at least 90% of LPH
items at V0 and V6) included 171 patients who were in-
cluded in responsiveness analyses. Table 5 presents pa-
tient demographic and clinical characteristics for the
baseline LPH population.
Quality of completion of the LPH
Over 85% patients had no missing items on the LPH at
both baseline and week 12. All LPH items had less than3% missing data at baseline and week 12. Responses were
well spread across the response scale. The results indicate
a good level of completion for the LPH items and ques-
tionnaires consistent with the benefits of a single page in-
strument and reports from the qualitative work that the
questionnaire was easy to complete.
Scaling properties and confirmation of the structure
of the LPH
Multitrait analysis performed on the LPH scale scores
and total score at baseline and visit 6/last visit indicated
that for both the Emotional and Physical scores all items
met the criteria for item convergent and item discrimin-
ant validity. Item-scale correlations ranged from 0.59-
0.76 for the ‘Emotional’ score and 0.43-0.78 for the
‘Physical’ score. For the Total score all but two items
met the test for item convergent validity (correlation
range: 0.38-0.72). Two items correlated with the Total
score at a level of r=0.38 which is just below the threshold
Table 6 Summary of LPH Properties
Dimension Structural properties of the LPH Percentages of patients having the lowest or highest possible LPH
scores























Visit 6/last visit LPH population
(N=176)















5 0.59-0.76 100% 100% 0 25 16 (8.42%) 6 (3.16%) 16 (9.09%) 2 (1.14%) 189 0.87 176 0.87
LPH Physical
score
8 0.43-0.78 100% 100% 0 40 4 (2.11%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 190 0.89 175 0.90
LPH Total
score
21 0.38-0.72 90% 100% 0 105 2 (1.05%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 185 0.92 171 0.92
1 Correlation between each item and its own scale corrected for overlap should be at least 0.40.











































6 Minute Walking Test
<300 m (N=33)
300 to <500 m (N=155)
Figure 3 Clinical validity of the LPH scores at baseline
according to the 6 Minute Walking Test (N=188).
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http://www.hqlo.com/content/11/1/161of acceptability (r=0.40). There was a moderate correlation
between the LPH Emotional and Physical scores (r=0.58)
indicating that the scales are related but not redundant and
high correlations between the LPH Total Score and both
the LPH Emotional score (r=0.85) and the LPH Physical
score (r=0.87), which indicates that the Total Score ad-
equately covers both physical and emotional dimensions.
At both baseline and week 12 the percentages of patients
with the lowest or highest possible score was low (<3%) for
all scales, indicating no floor or ceiling effect for the LPH
scores. These results indicate a good ability for patients to
both improve and worsen on the scales (Table 6). Finally,
strong internal consistency reliability of the LPH scores
was demonstrated by Cronbach’s alpha values of >0.70 for
all LPH scores at baseline and week 12 (Table 6).
Confirmatory factor analysis (CFA) of the LPH Emo-
tional and Physical scores at baseline indicated an average
overall fit for the items on the Emotional and Physical
scores. CFA of the LPH Total score at baseline indicated a
poor overall fit of the model with poor factor loadings for
most LPH items with only five items meeting the criteria
of 0.70.
Clinical validity
Results indicated that the LPH Physical and Total scores
were able to discriminate among groups of patients of
differing severity levels, as defined by World Health Or-
ganisation (WHO) functional class (Figure 2) and the six
minute walking test (Figure 3). The LPH Emotional score
did not discriminate between severity groups at a statisti-
cally significant level. Small sample sizes in WHO class I
and IV should be considered when interpreting these re-
sults. However, the LPH Emotional, Physical and Total
scores were broadly worse for those subjects with more se-
vere disease across clinical criteria.
Correlations were examined between LPH scores with
the Borg score at baseline and V6 (week 12). The highest
Borg correlations were with the LPH Physical score, as

























Figure 2 Clinical validity of the LPH scores at baseline
according to the WHO functional class (N=189).with the LPH Emotional Score (r=0.11 and r=0.15), and
the LPH Total Score (r=0.21 and r=0.23) were low.
Concurrent validity
The pattern of correlations between the LPH scores and
the concurrent measures was consistent with the con-
tent of the different scales, and so supportive of the val-
idity of the measure. Scales measuring similar concepts
correlated more highly than scales measuring dissimilar
concepts (Table 7). For example, the LPH Emotional
score correlated moderately with the EQ-5D anxiety/
depression item (0.59), but at a low level with EQ-5D
self-care (0.24).
Table 8 presents a summary of the responsiveness ana-
lyses for the LPH. The results provide some support for
the responsiveness of the Physical score and the Total
score, but not the Emotional score. For the Physical score
and the Total score, across all three methods of defining
change groups, effect sizes suggest there were small
to moderate improvements for the ‘improved’ group,
small improvements in the ‘stable’ group and negligible
change in the ‘worsened’ group. However, for the Emo-
tional score there were only small improvements in both
the ‘improved’ and ‘stable’ groups, and negligible change
in the worsened group. Moreover, the differences be-
tween change groups was only significant for the LPH
Physical and Total Score according to change in Borg
score (p=0.0073, p=0.0415 respectively).
Interpretation of the LPH Scores
Results to estimate the MID for the LPH scores using
anchor-based methods indicate an MID with a range of
1.48-3.69 for the LPH Emotional Score, 1.88 to 4.71 for
the LPH Physical Score and 4.41 to 11.02 for the LPH
Total score (Table 9).
Discussion
The results of this study provide evidence that the LPH
has strong content validity and psychometric validity as
Table 7 Validity of the LPH scores













Correlations with clinical parameters Baseline Week 12
Borg score 0.11 0.36 0.21 0.15 0.34 0.23
Concurrent validity with EQ-5D items Baseline (N=190) Week 12
Mobility 0.26 0.51 0.41 0.12 0.37 0.27
Self-Care 0.24 0.32 0.35 0.25 0.44 0.40
Usual Activities 0.36 0.46 0.45 0.30 0.48 0.41
Pain/Discomfort 0.35 0.36 0.40 0.23 0.28 0.27
Anxiety/Depression 0.59 0.42 0.53 0.51 0.34 0.41
EQ-5D VAS 0.26* 0.48 0.35 −0.20 −0.52 −0.36
EQ-5D index 0.49 0.53 0.57 −0.42 −0.52 −0.48
Bolded numbers = Statistically significant result.
*N=189.
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the symptoms and domains of impact elicited from the
patient interviews on to the LPH items indicated that
key symptom concepts relevant to PAH are assessed by
the LPH. A number of other symptoms were reported
by patients that are not directly assessed by the LPH,
but none of them were felt to be primary symptoms.
Moreover, although a wide range of additional impacts
were also mentioned, they were very personal and reflected
the individual’s living situation rather than their PAH ex-
perience and so would be unlikely to resonate with the
wider PAH population. While patients discussed a number
of emotional impacts that are not specifically addressed by
the LPH, including items to assess all of the emotional im-
pacts would add significant respondent burden. Further-
more, some of the concepts such as ‘upset’ and ‘feeling low’
are vague concepts, and ones which are to some extent
covered by the items that are included in the LPH (e.g.
feeling depressed). Considering patient burden and rele-
vance, the instrument captures all core symptom and im-
pact domains.
In addition to the concept elicitation results, when the
LPH was debriefed with patients it was well understood
and the questions were considered relevant, with no
concerns raised that key concepts were missing, thus
providing further evidence of content validity. The LPH
response options were understood well as evidenced by
the high proportion of patients who were able to rate
the symptoms and impact of PAH on different aspects
of their life as defined in the questionnaire. However,
some patients suggested further response descriptors in
addition to the existing ‘No’, ‘Very little’ and ‘Very much’
descriptors. While additional descriptors might be useful
in future versions of the LPH, their absence was unlikely
to have affected the ability of patients to complete thecurrent version of the LPH. Moreover, there is evidence
that increasing the number of categories does not always
provide a larger coverage of the target trait, and they
concluded that rating scales with fewer response categor-
ies were more functional [47]. Although many patients
found the ‘past week’ recall appropriate, some patients
felt this was too short a time period over which to con-
sider the impact of PAH on their lives. The FDA suggests
the use of shorter recall periods over longer periods; [13]
patients themselves note it would be harder for them to
accurately recall their symptoms over a longer period of
time. Thus, extending the recall period would not be
appropriate.
The results of scaling tests supported the a priori
structure of the LPH. However, as scale development is
an iterative process, some modifications to the LPH may
be warranted to improve the structure further for future
studies. Nevertheless, a trade-off between the advantages
and disadvantages of changing a well-validated and now-
well used scale with interpretation aids should be con-
sidered before making any modifications. The results of
a confirmatory factor analysis on the LPH Emotional
and Physical scales were positive, with goodness of fit
values indicating an average overall fit and moderate fac-
tor loadings on the factor analysis model. Further testing
using exploratory factor analysis could be considered to
explore whether an alternative structure of the LPH
would produce a better fitting model. However, as noted
above there is a trade-off to be considered when making
modifications to a well-validated and well-used instrument.
Internal consistency reliability results were very good for
the LPH sub-scale scores and the Total score indicating
that the LPH items included on each scale are measuring a
single underlying concept, without being redundant. These
results are consistent with those demonstrated by Rector
Table 8 Responsiveness of the LPH
Responsiveness
criteria
Value LPH emotional score LPH physical score LPH total score
Improved Stable Worsened p-value Improved Stable Worsened p-value Improved Stable Worsened p-value
WHO Functional Class N 37 123 10 p=0.9791 38 123 10 p=0.0976 37 123 10 p=0.5096
Mean Change −1.5 −1.6 −1.3 −4.2 −2.3 1.6 −6.3 −6.1 1.0
Effect Size −0.20 −0.22 −0.14 −0.54 −0.23 −0.19 −0.32 −0.27 0.04
Six Minute Walking test N 51 110 10 p=0.7050 51 110 10 p=0.1446 51 110 10 p=0.6578
Mean Change −1.7 −1.6 0.1 −3.3 −2.3 0.6 −6.7 −5.3 −3.4
Effect Size −0.22 −0.21 0.01 −0.35 −0.25 0.07 −0.29 −0.24 −0.16
Borg score N 36 121 13 p=0.2237 36 121 13 p=0.0073 36 121 13 p=0.0415
Mean Change −1.7 −1.6 0.5 −5.3 −1.9 0.2 −9.9 −4.9 0.3
Effect Size −0.26 −0.21 0.06 −0.61 −0.20 0.02 −0.46 −0.23 0.01























Table 9 Estimation of MID for the LPH from baseline to visit 6/last visit
LPH scores N Standard deviation at baseline MID using ES=0.2 MID using ES=0.5 MID using SEM
LPH Emotional score 190 7.38 1.48 3.69 2.66
LPH Physical score 190 9.41 1.88 4.71 3.12
LPH Total score 190 22.03 4.41 11.02 6.23
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heart failure patients [48]. It was not possible to evaluate
test-retest reliability as part of this study – such testing is
recommended as a priority in future evaluations of the
LPH.
Clinical validity was evaluated by examining the ability
of the instrument to discriminate between patients who
differed on key clinical indicators. The results provided
good evidence of clinical or known groups validity for
the Physical score and the Total score (with statistically
significant differences among groups), but limited support
for the clinical validity of the Emotional score. While the
pattern of mean scores for the emotional score was in line
with expectations, the differences between groups were not
statistically significant. However, low sample sizes for these
analyses, particularly in the case of WHO functional class
categories I and IV should be considered when interpreting
these results. In addition, the emotional subscale contains
fewer items than the physical subscale (5 vs. 8) and there-
fore differences in scores between clinical groups may not
be as apparent. Concurrent validity tests demonstrated that
in most cases there were moderate correlations between
the LPH scores and EQ-5D items that would be expected
to correlate. These results indicate that the two question-
naires are measuring similar concepts but are not redun-
dant with each other and are thus supportive of the validity
of the LPH. The clinical and concurrent validity properties
were comparable to those for similar scales on the CAM-
PHOR, a PAH specific instrument [12].
The responsiveness results provided mixed support re-
garding the ability of the LPH to reflect changes over
time, and suggest that the Physical score and the Total
score are more responsive to change over time than the
Emotional score. However, this is to be expected within
the context of a short term trial, as emotional function-
ing is typically more distal than physical functioning,
and is often less responsive to treatment. These findings
are consistent with those presented by Gilbert et al. in
reporting the MID for the 6MWD and Short Form-36
(SF-36); they similarly found that significant improvements
were only demonstrated for the 6MWD and SF-36 physical
functioning scale [9]. Overall, the responsiveness of the
LPH can be concluded to be acceptable. However, further
investigations of responsiveness are arguably warranted,
particularly to assess responsiveness to worsening and the
responsiveness characteristics of the Emotional scale within
the context of a larger scale study.Analyses to provide guidance for interpretation of LPH
scores using distribution-based methods indicated that for
all LPH scores there was a small range of MID definition.
Given this, based on an average of the results, a recom-
mendation for a change of three points on the sub-scales,
and a change of seven points on the Total score would be
considered as meeting the MID. This would translate as a
patient who experienced improvement in only a few areas
of their condition perceiving that they had experienced a
beneficial improvement in their quality of life. It is likely
that the ‘important’ or clinically important difference is
higher –around 4 points for the sub-scales and 11 points
for the Total score, as a 0.5 ES is easier to argue, given the
literature available to back it up [49,50]. Estimation of MID
using anchor-based methods could not be established in
this study due to correlations in LPH scores and change in
clinical parameters indicating no clear linear relationship.
Therefore, further investigation of MID using anchor-
based methods is recommended.
This study provide evidence supporting the use of the
LPH over other PAH specific instruments such as the
CAMPHOR. The original MLHFQ and now the LPH
have a strong history of published qualitative research
supporting content validity and use in clinical trials. The
evidence of these factors for the CAMPHOR is limited.
Although the CAMPHOR was developed specifically for
a PAH population, the development and validation sam-
ples were very homogenous, including only white Eng-
lish speaking patients, thus limiting the generalizability
of the instrument [12]. The LPH however, has been vali-
dated using a large sample of PAH patients across a range
of cultures and languages. The CAMPHOR authors also
acknowledge that a limitation of their instrument is lack of
evidence of responsiveness to treatment within a clinical
trial [12]. This paper provides evidence for the responsive-
ness of the LPH in an interventional study with PAH pa-
tients. Finally, the LPH can be considered a more suitable
instrument for use with PAH patients given its short length
(21 items), compared to the longer CAMPHOR (65 items)
and the fact it has clear, PAH-specific instructions, some-
thing the CAMPHOR lacks.
Limitations
Although this study provides strong support for the face
and content validity, and measurement properties of the
LPH there are some limitations that should be acknowl-
edged. The cut-points for the 6MWD and Borg Scale
Bonner et al. Health and Quality of Life Outcomes 2013, 11:161 Page 15 of 16
http://www.hqlo.com/content/11/1/161[44] as used for the responsiveness and MID analyses were
selected based on evidence from published literature. For
the 6MWD at the time of SAP design there was only one
published study which presented a suggested MID for the
6MWD in PAH. This study recommended an MID of
41m and a range of 18.70-74.15 [9] which the cut-point
used in this study was within. However, the authors are
aware that since the analyses were completed there have
been cut-points published for the two instruments that
could be considered more clinically relevant to distinguish
groups for clinical validity testing. For future studies and
further validation of the instruments such cut-points will
be considered.
The authors also note that it would have been benefi-
cial to collect haemodynamic characteristics in order to
characterise the sample, but unfortunately this was not
collected. However, it is still felt that the sample is well
characterised and clinically relevant.
Conclusion
Overall, this study provides evidence that the LPH has
good face and content validity in patients with PAH, has
strong psychometric properties and is appropriate for
use in clinical trials as a measure of core symptom and
impact concepts.
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